The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2024
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Fedin A.I.

Kafedra nevrologii Rossiĭskogo gosudarstvennogo meditsinskogo universiteta

The efficacy of cortexin and memantinol (memantine) in the treatment of cognitive impairment in patients with chronic cerebral ischemia

Authors:

Fedin A.I.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(1): 30‑36

DOI: 10.17116/jnevro20181181130-36

Views: 5054

Downloaded: 106

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Fedin AI. The efficacy of cortexin and memantinol (memantine) in the treatment of cognitive impairment in patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(1):30‑36. (In Russ.)
https://doi.org/10.17116/jnevro20181181130-36

Подписка 2025 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata

Objective. To study the dynamics of cognitive impairment in patients with chronic cerebral ischemia (CCI) treated with cortexin and memantinol (memantine). Material and methods. The authors present the results of the multicenter observational program «KORMEN» that studied the efficacy of cortexin and memantinol in the treatment of cognitive impairment in patients with CCI. The study included 495 patients, 204 (41.2%) men and 291 (58.8%) women. Patients were stratified into two groups: cortexin group (n=388 (78.4%)) and cortexin + memantinol group. Results and conclusion. A significant positive effect of treatment based on the scores on 4 cognitive scales was shown in both groups of patients. The addition of memantinol significantly improved cognitive functions in patients with severe cognitive impairment (р<0.05). The safety profile of the drugs was confirmed.

Keywords:

chronic cerebral ischemia
cognitive impairments
cortexin
memantinol

Authors:

Fedin A.I.

Kafedra nevrologii Rossiĭskogo gosudarstvennogo meditsinskogo universiteta

List of references:

  1. Vereshchagin NV, Piradov MA, Suslina ZA. Insul’t: printsipy diagnostiki, lecheniya I profilaktiki. M.: Intermedika; 2002. (In Russ.)
  2. Gusev EI, Skvortsova VI. Ishemiya golovnogo mozga. M.: Meditsina; 2001. (In Russ.)
  3. Yakhno NN. Cognitive impairment in neurological clinical practice. Nevrologicheskii zhurnal. 2006; 11(1)4-12. (In Russ.)
  4. Petersen RC. Aging, mild cognitive impairment and to Alzheimer’s disease. Neurological clinics. 2000;18:780-805.
  5. Fedin AI. Izbrannye lektsii po ambulatornoi nevrologii. XX Possisky naciohalnii congress «Chelovek I lekapstvo» M. 2013. (In Russ.)
  6. Zakharov VV, Lokshina AB. Cognitive impairment in discirculatory encephalopathy. RMZh. 2009;20:1325-1329. (In Russ.)
  7. Fedin AI, Putilina MV. Kognitivnye narusheniya v praktike terapevta. Uchebno-metodicheskoe posobie. Possisky gosydapstvennii medicinskii yniversitet. M. 2009. (In Russ.)
  8. Voronina TA. Farmakologiya nootropov. M.: Medicina; 1989. (In Russ.)
  9. Kovalev GV. Nootropnye sredstva. Volgograd. Nigne-Volgskoe knignoe izdatelstvo; 1990. (In Russ.)
  10. Garrett R, Grisham Ch. Molecular Aspects of Cell Biology. Fort Worth. Philadelphia etc.: Saunders Coll Publ; 1995.
  11. Muresanu D. Neurotrophiс Factors. Libripress. Bucuresti; 2003.
  12. Miller R. Calcium signaling in neurons. Trends Neurosci. 1988;30(1):46-48.
  13. Mayer M. Glutamate receptor ion channels. Curr Open Neurobiolog. 2005;15(3):282-288.
  14. Carrol RC, Zukin RS. NMDA-receptor trafficking and targeting; implications for synaptic transmission and plasticity. Trends Neuroscience. 2002;25:571-577.
  15. Debette S, Beiser A, DeCarli C. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke. 2010;41(4):574.
  16. Gavrilova S.I. Farmakoterapiya bolezni Al’tsgeimera. M.: Pul’s; 2003. (In Russ.)
  17. Leys D, Englund E, Erkinjuntti T. Vascular dementia. In: Evidence-based Dementia Practice. Ed. by N. Qizilbash et al. Oxford etc.: Blackwell Science; 2002.
  18. De Haan EH, Nys GM, Van Zandvoort MJV. Cognitive function following stroke and vascular cognitive impairment. Current Opinion in Neurology. 2006;19:559-564.
  19. Darby D, Maruff P, Collie А. Mild cognitive impairment can be detected by multiple assessments in a single day. Neurology. 2002;59(7):1042-1046.
  20. Gudkova AA, Sorokina IB, Yakovlev AA. The use of the drug akatinol memantine in patients with vascular cognitive disorders. Zhurnal nevrologii i psikhiatriiimeni S.S. Korsakova. 2010;110:12:37-140. (In Russ.)
  21. Gusev EI, Avakyan GN, Bogolepova AN. Evaluation of the efficacy of therapy with akatinol memantine in patients with vascular dementia and Parkinson’s disease. Zhurnal Atmosfera. Nervnye bolezni. 2007;1:11-23. (In Russ.)
  22. Mark LP, Prost RW, Ulmer JL. Pictorial review of glutamate excitotoxicity: Fundamental concepts for neuroimaging. American Journal of Neuroradiology. 2001;22:1813-1824.
  23. Gomazkov OA. Neurotrophins: therapeutic potential and concept of minipeptides. Neirokhimiya. 2012;3:1-11. (In Russ.) https://doi.org/10.1134/s1819712412030075
  24. Morozov VG, Khavinson VKh. Peptidnye bioregulyatory (25-letnii opyt eksperimental’nogo i klinicheskogo izucheniya). SPb.: Nauka; 1996. (In Russ.)
  25. Orgogozo JM, Rigaud AS, Stoffler A. Efficacy and safety of Memantine in patients with mild to moderate vascular dementia: A randomized, placebo-controlled trial (MMM-300). Stroke. 2002;33(7):1834-1839.
  26. Gomazkov OA. Starenie mozga i neirotroficheskaya terapiya. M.: IKAR; 2011. (In Russ.)
  27. Golovko AI. Neurotrophic factors of the brain. Neirokhimiya. 2008;25(4):261-271. (In Russ.) https://doi.org/10.1134/s1819712408040016
  28. Gomazkov OA. Cortexin: molecular mechanisms and targets of neuroprotective activity. Zhurnal nevrologii i psikhiatriiim. S.S. Korsakova. 2015;115(8):99-104. (In Russ.) https://doi.org/10.17116/jnevro20151158199-104
  29. D’yakonov MM. To the question of the neuroprotective action of peptide medicines. Vestnik Rossiiskoi voenno-meditsinskoi akademii. 2011;3(33):255-258. (In Russ.)
  30. Rudenko AO, Eltysheva TE, D’yakonov MM. Effect of the amino acid spectrum of peptide organopreparations on the effectiveness of pharmacotherapy. Vestnik Rossiiskoi voenno-meditsinskoi akademii. 2017;1(57):129-136. (In Russ.)
  31. Mashin VV, Belova LA, Chaplanova OI. An open clinical trial of cortexin in dyscirculatory encephalopathy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2014;114(9):49-52. (In Russ.)
  32. Dingledine R, Borges K, Bowie D. The glutamate receptor ion channels. Pharmacological Reviews. 1994;51:7-61.
  33. Levin OS, Yunishchenko NA, Dadurova MA. Efficacy of akatinol memantine in moderate cognitive impairments. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2009;109(7):36-42. (In Russ.) https://doi.org/10.1007/s11055-010-9347-8

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.